About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 875 record(s)
Req # A-2023-000149
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 for the medicinal ingredient Enzalutamide; The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for Enzalutamide; The strength (s) and dosage form of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.; The Canadian Reference product used to support of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.; Any information pertaining to a Risk Management Plan (RMP) submitted to support of any and all generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-03-24 having the medicinal ingredient Enzalutamide.Organization: Health Canada
November 2023
Req # A-2023-000445
All records pertaining to the priority review request and decision of lecanemab submitted by Biogen Inc. and Eisai Co., Ltd. to Health Canada. Time period: January 2022 to June 28, 2023.Organization: Health Canada
November 2023
Req # A-2023-000518
All documents, from January 1, 2023, respecting the House of Commons committee consideration of contracts awarded to McKinsey & Company.Organization: Health Canada
November 2023
Req # A-2023-000580
Obtain the briefing file(s) to be provided to Mark Holland, Canada's new Minister of Health, as soon as he takes the position today, July 26, 2023.Organization: Health Canada
November 2023
Req # A-2023-000595
Any briefing materials prepared for the new minister of mental health and addictions who was sworn in on July 26, 2023.Organization: Health Canada
November 2023
Req # A-2023-000643
Briefing booklet/notes provided to incoming minister of health Mark Holland ahead of his July 26, 2023 appointment to the role.Organization: Health Canada
November 2023
Req # A-2023-000749
Obtain the briefing file(s) for the new Minister Ya'ara Saks, appointed in July 2023.Organization: Health Canada
November 2023
Req # A-2023-000761
The following contracts: Reference number: C-2021-2022-Q4-00796 HC Procurement Identification: H105125451. Reference number: C-2021-2022-Q4-00798 HC Procurement Identification: H105125521. Reference number: C-2022-2023-Q1-00533 HC Procurement Identification: H105124231.Organization: Health Canada
November 2023
Req # A-2023-000826
Health Canada currently has two generic submissions under review for the drug Eplerenone. The following information for these submissions: Date of application Manufacturer or Company Class, Product type Submission type Canadian reference product Dosage form Route(s) of administration Medical ingredient(s) Strength.Organization: Health Canada
November 2023
Req # A-2023-000883
The briefing book prepared by the Department for the incoming new Minister of Health, Mark Holland following the recent cabinet shuffle.Organization: Health Canada
November 2023